{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:10:06Z","timestamp":1789420206468,"version":"build-2803163510"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute leukemia (AL) is a hematological malignancy, and the prognosis of most AL patients hasn\u2019t improved significantly, particularly for relapsed or refractory (R\/R) AL. Therefore, new treatments for R\/R adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are urgently necessary. Novel developments have been made in AL treatment, including target and immune therapies. CD38 is one of the targets due to its high expression in many hematological malignancies, including multiple myeloma, ALL and a subset of AML. Consequently, targeting CD38 therapies, including CD38 monoclonal antibodies (mAbs), bispecific antibodies, and CAR-T cell therapy, exhibit promising efficacy in treating multiple myeloma without significant toxicity and are being explored in other hematological malignancies and nonhematological diseases. Herein, this review focuses on targeting CD38 therapies in ALL and AML, which demonstrate sound antileukemic effects in acute leukemia and are expected to become effective treatment methods.<\/jats:p>","DOI":"10.3389\/fonc.2022.1007783","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T08:13:58Z","timestamp":1665562438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting CD38 for acute leukemia"],"prefix":"10.3389","volume":"12","author":[{"given":"Xushu","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the united states","volume":"9","author":"Pulte","year":"2014","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(81)90441-4","article-title":"Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10","volume":"23","author":"Terhorst","year":"1981","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.145.3.878","article-title":"CD38 molecule: Structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells","volume":"145","author":"Alessio","year":"1990","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2012.06.017","article-title":"Tetrameric interaction of the ectoenzyme CD38 on the cell surface enables its catalytic and raft-association activities","volume":"20","author":"Hara-Yokoyama","year":"2012","journal-title":"Structure"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.05.012","article-title":"Crystal structure of human CD38 extracellular domain","volume":"13","author":"Liu","year":"2005","journal-title":"Structure"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830131211","article-title":"Chromosome assignment of monoclonal antibody-defined determinants on human leukemic cells","volume":"13","author":"Katz","year":"1983","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.4049\/jimmunol.159.8.3858","article-title":"Human CD38, a leukocyte receptor and ectoenzyme, is a member of a novel eukaryotic gene family of nicotinamide adenine dinucleotide+-converting enzymes: extensive structural homology with the genes for murine bone marrow stromal cell antigen 1 and aplysian ADP-ribosyl cyclase","volume":"159","author":"Ferrero","year":"1997","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15429","DOI":"10.1074\/jbc.273.25.15429","article-title":"Molecular mechanism of human CD38 gene expression by retinoic acid. identification of retinoic acid response element in the first intron","volume":"273","author":"Kishimoto","year":"1998","journal-title":"J Biol Chem"},{"key":"B13","first-page":"81","article-title":"Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues","volume":"12","author":"Fernandez","year":"1998","journal-title":"J Biol Regul Homeost Agents"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.160.3.1106","article-title":"Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells","volume":"160","author":"Cesano","year":"1998","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1324","article-title":"Mice deficient for the ectonicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses","volume":"92","author":"Cockayne","year":"1998","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1042\/bj3620125","article-title":"CD38 is the major enzyme responsible for synthesis of nicotinic acidadenine dinucleotide phosphate in mammalian tissues","volume":"362","author":"Chini","year":"2002","journal-title":"Biochem J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)74275-6","article-title":"Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP","volume":"268","author":"Takasawa","year":"1993","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"30327","DOI":"10.1074\/jbc.270.51.30327","article-title":"ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP","volume":"270","author":"Aarhus","year":"1995","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/18024","article-title":"Regulation of calcium signaling in T lymphocytes by the second messenger cyclic ADP-ribose","volume":"398","author":"Guse","year":"1999","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2280","article-title":"Expression of CD38 gene, but not of mitochondrial glycerol-3-phosphate dehydrogenase gene, is impaired in pancreatic islets of GK rats","volume":"214","author":"Matsuoka","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500591","article-title":"CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation","volume":"195","author":"Morandi","year":"2015","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.2416","article-title":"A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes","volume":"196","author":"Zocchi","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2308.bloodjournal8762308","article-title":"Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane","volume":"87","author":"Ramaschi","year":"1996","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199208000-00004","article-title":"Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection","volume":"6","author":"Kestens","year":"1992","journal-title":"AIDS"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1309\/3G1XDX0DVHBNVKB4","article-title":"Immunophenotypic profile of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia","volume":"124","author":"Konoplev","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"B29","first-page":"853","article-title":"AL amyloidosis. characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies","volume":"71","author":"Perfetti","year":"1994","journal-title":"Lab Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-007-0029-5","article-title":"Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma","volume":"24","author":"Todorovic","year":"2007","journal-title":"Med Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24571","article-title":"CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): possible biomarkers for novel targeted therapies","volume":"92","author":"Zaja","year":"2017","journal-title":"Am J Hematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1186\/1471-2407-14-890","article-title":"CD30 expression is a novel prognostic indicator in extranodal natural killer\/T-cell lymphoma, nasal type","volume":"14","author":"Li","year":"2014","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"key":"B34","article-title":"Immunophenotypic significance of the lymphoid Cd38 antigen in myeloid blood malignancies","volume":"40","author":"Marinov","year":"1993","journal-title":"Neoplasma"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00147-2","article-title":"Increased CD38 expression is associated with favorable prognosis in adult acute leukemia","volume":"24","author":"Keyhani","year":"2000","journal-title":"Leuk Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.12122\/j.issn.1673-4254.2020.11.16","article-title":"Analysis of immunophenotypes and expressions of non-myeloid antigens in acute myeloid leukemia","volume":"40","author":"Weiwei","year":"2020","journal-title":"J South Med Univ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"haematologica"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1182\/blood.V124.21.2312.2312","article-title":"Anti-leukemic activity of daratumumab in acute myeloid leukemia cells and patient-derived xenografts","volume":"124","author":"Dos Santos","year":"2014","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1182\/blood-2018-99-110527","article-title":"Inecalcitol enhances daratumumab-induced antibody-dependent cell cytotoxicity towards multiple myeloma and acute myeloid leukemia cell lines","author":"Mouly","year":"2018","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijlh.12716","article-title":"Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients","author":"Jalal","year":"2017","journal-title":"Int J Lab Hem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0058","article-title":"Evaluation of preclinical activity of isatuximab in patients with acute lymphoblastic leukemia","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000630","article-title":"Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for antiCD38 immunotherapy","volume":"8","author":"Tembhare","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.1123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"186","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.01.028","article-title":"Complement in therapy and disease: regulating the complement system with antibody-based therapeutics","volume":"67","author":"Melis","year":"2015","journal-title":"Mol Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"22062","DOI":"10.1038\/s41598-021-01300-8","article-title":"Targeting CD38 in acute myeloid leukemia interferes with leukemia trafcking and induces phagocytosis","volume":"11","author":"Farber","year":"2021","journal-title":"Scientifc Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.1008.1110","article-title":"Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways","volume":"101","author":"Preyat","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/cells4030520","article-title":"NAD+-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews tcell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242974","article-title":"Daratumumab inhibits acute myeloid leukemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells","volume":"106","author":"Mistry","year":"2021","journal-title":"haematologica"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"key":"B55","article-title":"Daratumumab treatment alone or in combination with vincristine results in the inhibition of tumor growth and long term survival in preclinical models of acute lymphocytic leukemia","volume":"99","author":"Doshi","year":"2014","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0222-5","article-title":"Daratumumab at the frontiers of posttransplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy","volume":"53","author":"Bonda","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16154","article-title":"Will daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia","volume":"187","author":"Mirgh","year":"2019","journal-title":"Br J Haematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28829","article-title":"Daratumumab in T-cell acute lymphoblastic leukaemia: A case report and review of the literature","volume":"68","author":"Sandra","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2018-99-113287","article-title":"Inhibition of CD38 shows anti-leukemic activity in acute myeloid leukemia","volume":"132","author":"Farber","year":"2018","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20745","article-title":"Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels","volume":"97","author":"Lamkin","year":"2006","journal-title":"J Cell Biochem"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy040","article-title":"Anti-leukemic effects of all-trans retinoic acid in combination with daratumumab in acute myeloid leukemia","volume":"30","author":"Buteyn","year":"2018","journal-title":"Int Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-021-00291-y","article-title":"Venetoclax and daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of acute myeloid leukemia","volume":"9","author":"Mistry","year":"2021","journal-title":"biomark Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.753145","article-title":"Interferon- promotes antibody-mediated fratricide of acute myeloid leukemia cells","volume":"291","author":"Fatehchand","year":"2016","journal-title":"J Biol Chem"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1182\/blood.V124.21.4727.4727","article-title":"Immunotherapy with long-lived anti-CD389 anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: a potential therapy for multiple myeloma","volume":"124","author":"Chu","year":"2014","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2021-149329","article-title":"A phase 1 study of XmAb18968, a CD3-CD38 bispecific antibody for the treatment of patients with Relapsed\/Refractory acute leukemia and T cell lymphoblastic lymphoma","volume":"138","author":"Guru Murthy","year":"2021","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.73","article-title":"All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia","volume":"5","author":"Yoshida","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0355-5","article-title":"Efficiency and side effects of anti-CD38 CAR-T cells in an adult patient with relapsed b-ALL after failure of bi-specific CD19\/CD22 CAR-T cell treatment","volume":"17","author":"Guo","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1007783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T23:59:01Z","timestamp":1678233541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1007783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":72,"alternative-id":["10.3389\/fonc.2022.1007783"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1007783","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"article-number":"1007783"}}